Verrica Pharmaceuticals Inc. has announced a reverse stock split, converting every 10 shares of its common stock into one share. This change, effective July 24, 2025, aims to consolidate the company's share structure. As a result, the number of outstanding shares will drop from approximately 92.5 million to 9.25 million. The stock will begin trading on a split-adjusted basis on The Nasdaq Global Market on July 25, 2025, with a new CUSIP number, 92511W207. No fractional shares will be issued; shareholders will receive cash for any fractional entitlements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-162939), on July 23, 2025, and is solely responsible for the information contained therein.